A new mechanism of action proposed for ramoplanin [10]

Journal of the American Chemical Society

Volumn 122, Issue 14, 2000, Pages 3540-3541

  Lo, Mei Chu ^a   Men, Hongbin ^b   Branstrom, Arthur ^b   Helm, Jeremiah ^c   Yao, Nan ^a,d   Goldman, Robert ^a,b   Walker, Suzanne ^b  

^a Incara Pharmaceulicals ^*  (United States)

^b PRINCETON UNIVERSITY   (United States)

^c Incara Pharmaceuticals ^*  (United States)

^d Princeton University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAMOPLANIN;

ANTIMICROBIAL ACTIVITY; CELL MEMBRANE PERMEABILITY; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; LETTER; POLYMERIZATION; STOICHIOMETRY; TRANSMISSION ELECTRON MICROSCOPY;

EID: 0034640026     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja000182x     Document Type: Letter

References (23)

1. Somner, E. A.; Reynolds. P. E. Antimicrob. Agents Chemother. 1990, 34, 413-419.
2. Reynolds, P. E.; Somner. E. A. Drug. Exptl. Clin. Res. 1990, 16, 385-389.
3. Brötz.; H.; Bierbaum. G.; Reynolds, P. E.; Sahl, H.-G. Eur. J. Biochem. 1997, 246, 193-199.
4. 14C]-UDP-GlcNAc (0.83 μM. 300 mCi/mmol) were added to E. coli membranes in the presence of Triton-X. Following depletion of UDP-GlcNAc, the Triton-X was removed, and the polymerization of radiolabled Lipid II was monitored as described in:
5. Park, W.; Matsuhashi, M. J. Bacteriol. 1984, 157, 538-544.
6. Ramoplanin alters the chromatographic mobility of Lipid II, but nothing else is known regarding the structure of the complex. See: Brötz, H.; Josten. M.; Wiedemann, I.; Schneider. U.; Götz, F.; Bierbaum, G.; Sahl. H.-G. Mol. Microbiol. 1998, 30, 317-327.
7. NMR structures of ramoplanin and analogues have been reported previously. See: (a) Skelton, N. J.; Harding, M. M.; Mortishire-Smith, R. J.: Rahman, S. K.; Williams, D. H.; Ranee, M. J.; Ruddock, J. C. J. Am. Chem. Soc. 1991, 113, 7522-7530.
8. (b) Maplestone, R. A.; Cox. J. P. L.; Williams, D. H. FEBS Lett. 1993, 326, 95-100.
9. Kurz, M.: Guba. W. Biochemistry 1996, 35, 12570-12575.
10. (a) Men, H.; Park. P.; Ge, M.; Walker. S. J. Am. Chem. Soc. 1998, 120, 2484-2485.
11. (b) Ha, S.; Chang. E.; Lo, M.-C; Men. H.; Park. P.; Ge. M.; Walker, S. J. Am. Chem. Soc. 1999, 121, 8415-8426.
12. +], 1265.6: found, 1266.
13. Imperiali and co-workers used a chemo-enzymatic route to make the substrate for oligosaccharyl transferase. See: Imperiali, B.; Zimmerman, J. W. Tetrahedron Lett. 1990, 31, 6485-6488.
14. We have established that ramoplanin inhibits the MurG-catalyzed transfer of GlcNAc to 1 in the absence of membranes, showing that the molecule retains inhibitory potency in solution, and providing a justification for studying ramoplanin complexes in solution.
15. Synthetic cylic peptides comprised of alternating D and L amino acids have been observed to form self-assembling peptide nanotubes. See: (a) Ghadiri, M. R.: Granja, J. R.; Milligan, R. A.; McRee, D. E.; Khazanovich, N. Nature 1993, 366, 324-327.
16. (b) Hartgerink, J. D.: Granja, J. R.; Milligan. R. A.; Ghadiri, M. R. J. Am. Chem. Soc: 1996, 118, 43-50.
17. Cann, J. R. Methods Enzymol. 1978, 48, 299-307.
18. Vancomycin and some other glycopeptide antibiotics are proposed to utilize cooperative interactions between complexes to enhance substrate binding. See inter alia: Williams, D. H. Nat. Prod. Rep 1996, 13, 469-477.
19. (a) Sahl, H.-G.; Bierbaum. G. Annu. Rev. Micmhiol. 1998, 52, 41-79.
20. (b) Brötz, H.: Bierbaum. G.: Leopold, K.: Reynolds, P. E.; Sahl, H.-G. Antimicrob. Agents Chemother. 1998, 42, 154-160.
21. (c) Breukink, E.: Wiedemann, I.; van Kraaij, C.; Kulpers. O. P.: Sahl. H.-G.; de Kruijff, B. Science 1999, 286, 2361-2364.
22. Malabarba, A.; Nicas. T. I.: Thompson. R. C. Med. Res. Rev. 1997. 17, 69-137.
23. Ge. M; Chen, Z.; Onishi, H. R.; Kohler. J.; Silver. L. L.: Kerns. R.; Fukuzawa. S.; Thompson. C.: Kahne. D. Science 1999, 284, 507-511